4 years ago

Histone Deacetylase Inhibitors in Tumor Immunotherapy.

Zhao LM, Zhang JH
With an increasing understanding of the antitumor immune response, considerable progress has been made in the field of tumor immunotherapy in the last decade. Inhibition of HDACs represents a new strategy in tumor therapy and HDAC inhibitors have been recently developed and validated as potential antitumor drugs. In addition to the direct antitumor effects, HDAC inhibitors have been found to have the ability to improve tumor recognition by immune cells that may contribute to their antitumor activity. These immunomodolutory effects are desirable, and their in-depth comprehension will facilitate the design of novel regimens with improved clinical efficacy. In this review, we summarize recent advances in the understanding of how HDAC inhibitors alter immune process and discuss their effects on various cytokines. We also discuss the challenges to optimize the use of these inhibitors as immune modulators in cancer treatment, which may be helpful for designing tumor immunotherapy trials involving HDAC inhibitors.

Publisher URL: https://www.ncbi.nlm.nih.gov/pubmed/28762309

DOI: PubMed:28762309

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.